2020
Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment And Research Communications 2020, 24: 100196. PMID: 32769037, DOI: 10.1016/j.ctarc.2020.100196.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAftercareAntineoplastic Agents, ImmunologicalBiomarkers, TumorButyrophilinsColorectal NeoplasmsComplementarity Determining RegionsComputational BiologyDisease-Free SurvivalExomeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateReceptors, Antigen, B-CellReceptors, Antigen, T-CellRecombination, GeneticRNA-SeqSurvival RateConceptsSurvival rateLung cancerColon cancerImmune receptor recombinationsWorse survival rateCancer survival ratesCases of melanomaBetter survival rateB cell receptorFamily membersSurvival distinctionsCancer Genome AtlasImmunotherapy approachesColorectal adenocarcinomaT cellsImmunogenomics studiesCancer typesCancerConsistent associationHigh expressionGenome AtlasImmune receptorsImmunogenomic featuresMelanomaCancer exomes
2018
Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates
Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research And Treatment 2018, 173: 167-177. PMID: 30229447, DOI: 10.1007/s10549-018-4961-1.Peer-Reviewed Original ResearchConceptsImmune receptor recombinationsSpecific HLA allelesExome filesHLA typesBreast cancerHLA allelesSurvival rateImmune checkpoint inhibitor therapyImproved disease-free survivalDisease-free outcomeCheckpoint inhibitor therapyT cell receptor VUse of immunotherapyDisease-free survivalSegment usageB cell biomarkersBreast cancer subgroupsHLA allele combinationsBetter survival rateBreast cancer samplesBreast tumor samplesGene segment usageSurvival distinctionsInhibitor therapyImmune characterization